麥迪衞康(02159.HK)2020年淨利同比增長0.91%至2104.2萬元
格隆匯 3 月 26日丨麥迪衞康(02159.HK)公吿，截至2020年12月31日止年度的全年業績，收入人民幣(下同)4.32億元，同比增長1.20%；公司擁有人應占溢利2104.2萬元，同比增長0.91%；基本每股盈利14.03分。
在2020年初，集團透過麥迪衞康醫加醫療平台發現數百萬卒中患者因新冠肺炎疫情爆發而無法親身前往醫院就醫或複診，立即與中國卒中學會攜手共同開展"共抗疫情－健康守護者行動"，配合診斷、救治工作，服務數百萬無法親身前往醫院就醫的腦血管病患者，保障他們依然能享受到常規及及時的診療服務，幫助和指導高危人羣預防卒中發生。
2020年下半年，麥迪衞康與石藥集團有限公司達成戰略合作，為國內卒中患者推出"卒中患者標準化院外管理項目"，提供出院後諮詢、隨訪、複診檢查、電子處方及送藥到家等一站式院外管理方案，目前已覆蓋全國十個省份並不斷擴展，另已搭建卒中患者標準化院外管理體系，滿足卒中患者"用藥＋複診＋檢查"的持續性專業診療需求。
為滿足廣大醫生對學術內容、持續教育的需求和廣大患者對疾病知識、健康宣教內容的需求，麥迪衞康與非政府組織("NGO組織")合作，開展線上、線下醫生教育活動及患者教育活動。
其中，中國卒中學會第六屆學術年會暨天壇國際腦血管病會議2020(CSA&TISC2020)以線上+線下的形式舉辦，共覆蓋醫生約15萬人次。在10月29日世界卒中日前後，集團通過其醫療平台開展線上免費健康諮詢和義診活動，協助中國卒中學會開展了面向全國的"2020年世界卒中日全國健康科普志願行動"。互聯網醫療服務是集團重要的發展方向。
優質的醫生資源是提供互聯網醫療服務能力的保證，集團通過其專供患者使用的微信公眾號麥迪衞康醫加及專供醫生使用的移動應用程式醫加醫生端獲取專業及優質的醫生資源，為患者提供疾病管理服務；截至2020年12月31日，醫加醫生端的醫生註冊用户數達到18,781人，較2019年增長逾60倍，而麥迪衞康醫加的患者用户數達25,874人，較2019年增長逾20倍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
